InMed Pharmaceuticals Inc.
INM · NASDAQ
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Revenue | $4,943 | $4,598 | $4,136 | $1,089 |
| % Growth | 7.5% | 11.2% | 279.6% | – |
| Cost of Goods Sold | $3,236 | $3,497 | $2,733 | $546 |
| Gross Profit | $1,707 | $1,101 | $1,403 | $544 |
| % Margin | 34.5% | 23.9% | 33.9% | 49.9% |
| R&D Expenses | $2,854 | $3,218 | $3,732 | $7,283 |
| G&A Expenses | $6,558 | $5,798 | $5,848 | $6,867 |
| SG&A Expenses | $6,558 | $5,798 | $5,848 | $6,867 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $213 | $220 | $202 | $186 |
| Operating Expenses | $9,625 | $9,235 | $9,782 | $14,335 |
| Operating Income | -$7,918 | -$8,134 | -$8,379 | -$13,792 |
| % Margin | -160.2% | -176.9% | -202.6% | -1,266% |
| Other Income/Exp. Net | -$244 | $466 | $444 | -$4,808 |
| Pre-Tax Income | -$8,162 | -$7,668 | -$7,935 | -$18,600 |
| Tax Expense | $0 | $7 | $13 | $0 |
| Net Income | -$8,162 | -$7,676 | -$7,948 | -$18,600 |
| % Margin | -165.1% | -166.9% | -192.2% | -1,707.3% |
| EPS | -11.44 | -27.55 | -86 | -21,350.51 |
| % Growth | 58.5% | 68% | 99.6% | – |
| EPS Diluted | -11.44 | -27.55 | -86 | -21,350.51 |
| Weighted Avg Shares Out | 976 | 381 | 122 | 1 |
| Weighted Avg Shares Out Dil | 976 | 381 | 122 | 1 |
| Supplemental Information | – | – | – | – |
| Interest Income | $157 | $722 | $652 | $124 |
| Interest Expense | $373 | $0 | $0 | $0 |
| Depreciation & Amortization | $535 | $605 | $596 | $512 |
| EBITDA | -$7,256 | -$7,064 | -$7,783 | -$13,280 |
| % Margin | -146.8% | -153.6% | -188.2% | -1,219% |